Global CDMO Scale Catalent operates a global network with over 40 sites and 10,001+ employees, supporting more than 60 billion doses annually. Sales opportunities lie in expanding multi-site CDMO collaborations, integrated development and manufacturing services, and multi-modality capabilities for large pharma and biotech clients.

High Development Activity With over 1,000 active development programs at any time and frequent product launches, there is substantial demand for early‑stage development, analytical testing, and accelerated manufacturing readiness. Target partnerships around early development platforms and rapid scale‑up services.

Strategic Partnerships Recent and ongoing collaborations with gene therapy, cell therapy, and regenerative medicine players indicate a strong pipeline for specialized manufacturing and licensure. Focus on offering cGMP manufacturing, process development, and commercial supply for high‑touch therapies.

Quality and AI Innovation Launch of Qai, Catalent’s enterprise AI tool for quality systems signals a priority on quality, compliance, and efficiency. Sales opportunities exist in offering advanced QA/QA integration, data digitization, and process optimization services to reduce risk and time‑to‑market.

Risk and Compliance Signals Recent news about facility adjustments in regulatory filings suggests a need for flexible, risk‑mitigated manufacturing strategies and site‑specific compliance support. Position offerings around scalable, risk‑aware manufacturing partnerships and contingency planning.